The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
 
Melinda L. Telli
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Guardant Health; Merck; Natera; Novartis; Reflexion Medical; Replicate Bioscience; Sanofi
Research Funding - Abbvie (Inst); Arvinas (Inst); Bayer (Inst); Biothera (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Tesaro (Inst)
Other Relationship - G1 Therapeutics
 
Chelsea D. Gawryletz
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Seagen
 
Mei Wei
Consulting or Advisory Role - bioTheranostics; Gilead Sciences; Gilead Sciences
Patents, Royalties, Other Intellectual Property - From Ambry Genetics for a software (I)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Dongrui R. Lu
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Marco Mazzoletti
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Olga Valota
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Swapnil S Parmar
Employment - Arvinas; AstraZeneca/MedImmune; PRA Health Sciences
Stock and Other Ownership Interests - Arvinas; Pfizer
 
Weiwei Tan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai; Micin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Gilead Sciences (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst)